U.S. FDA Issues Complete Response Letter for Baricitinib (NYSE:LLY)

INDIANAPOLIS--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA).



U.S. FDA Issues Complete Response Letter for Baricitinib (NYSE:LLY)